Case Studies
Real outcomes. Real data. Real people.
Detailed, anonymised case studies from our patient cohort. Every number is real. Every chart is taken directly from our monitoring system. Every case is published with the patient’s written consent.
- Why Publish These
Evidence, not adjectives.
Most clinics talk about results in adjectives — life-changing, transformative, breakthrough. We’d rather show you the numbers.
The case studies below come directly from our internal monitoring platform. Every score is a real clinical assessment, taken at a real point in someone’s treatment. Where we use a patient’s words, those words are theirs — sometimes paraphrased to protect identity, never invented.
We publish these because the only way to make ketamine therapy understandable for people who haven’t experienced it is to show them what it looks like in practice. And because the people we treat deserve to see real evidence before they spend real money.
- All cases anonymised
- Published with written consent
- Clinical data verified by treating consultant
- Case Study #1
10+ Years of Failed Treatment. 9 Weeks to Recovery.
A 42-year-old London professional who tried everything — and finally found what worked.
Photo is an anonymised representation to protect patient privacy.
“I spent years just getting through each day. This is the first time I’ve felt like myself again.”
10+ Years
living with depression
5 Treatments
tried without success
9 Weeks
Save Minds programme
80% Reduction
in depression score
What Didn't Work
5 previous treatments over 10 years — no lasting relief.
- Treatment #1 · SSRI · 2013–14 · Minimal improvement
- Treatment #2 · SNRI · 2014–16 · Side effects, no relief
- Treatment #3 · SSRI · 2016–18 · Brief response, then return
- Treatment #4 · Therapy + SSRI · 2018–20 · Limited benefit
- Treatment #5 · SNRI · 2020–22 · No response
Measured Results
Clinically validated scores — before & after.
Depression (PHQ-9)
80% reduction
Before
After
Anxiety (GAD-7)
Severe → Mild
Before
After
Rumination
50% reduction
Before
After
Wellbeing
Marked improvement
Before
After
Daily Mood
Stable improvement
Before
After
The Reality Before Treatment
Despite appearing high-functioning at work, his internal experience was very different: daily anxiety from the moment he woke, persistent low mood and emotional exhaustion, intrusive repetitive thoughts about his health, chronic muscle tension and pain, poor sleep, low energy. He continued working and supporting his family — but at significant personal cost.
What Met the Criteria for Treatment-Resistance
Five antidepressants trialled — four SSRIs and one SNRI — all at appropriate doses and durations. No sustained remission. By clinical definition, this meets the criteria for treatment-resistant depression. He was also taking Pregabalin (150 mg) for anxiety — providing partial symptom relief at best.
The Save Minds Programme
He completed a 9-week treatment programme designed for patients who haven’t responded to traditional antidepressants. The approach focused on resetting dysfunctional brain pathways, enhancing neuroplasticity, reducing rumination cycles, and supporting lasting psychological change. Progress was tracked daily.
By the End of Treatment
He experienced dramatically reduced depression and anxiety scores, improved sleep and energy, reduced physical tension and pain, greater emotional stability, and a renewed sense of control. The depression PHQ-9 score moved from 20 (severe) to 4 (minimal). Suicidal ideation, present at intake, resolved completely by week 5 and remained at zero throughout the rest of the programme.
- Case Study #2
9 Clinical Scales. Every One Improved.
Comprehensive tracking across depression, anxiety, OCD, PTSD, rumination, suicidality and wellbeing — all moving in the right direction.
Photo is an anonymised representation to protect patient privacy.
“For the first time in years, the numbers confirm what I feel — I’m actually getting better.”
9
Scales Tracked
Across all conditions
80%
Depression Drop
PHQ-9
74%
Anxiety Drop
GAD-7
0
Suicide Risk
C-SSRS
Measured Progress
Clinically validated scores — start vs. latest.
Depression (PHQ-9) – Severe → Minimal
80%
Now: 4 / 27
Start: 20
Anxiety (GAD-7) – Severe → Mild
74%
Now: 5 / 21
Start: 19
OCD (Y-BOCS) – Severe → Mild
54%
Now: 13 / 40
Start: 28
Rumination (RRS-10) – Moderate → Low
50%
Now: 14 / 40
Start: 28
PTSD (NSESSS) – Below threshold → Below threshold
Maintained
Now: 7 / 36
Start: 11
Wellbeing (WEMWBS) – Very Low → Below Average
Marked improvement
Now: 46 / 70
Start: 33
- Across the Cohort
The wider picture, in numbers.
Individual cases tell stories. Aggregated data tells you whether those stories are typical. Below is our outcomes data across 900+ patients and over 5,000 treatments.
75%+
Good response rate
Across all conditions
50%
See significant change in first 10 sessions
Depression & anxiety
75%+
Of patients achieve good response by session 20
Complete programme
75%+
Of severely suicidal patients have ideation fully resolved within 6–8 sessions
C-SSRS
Internal audit data, awaiting peer-reviewed publication. Last updated: 2026.
- Browse By Condition
More cases across each condition.
We’re publishing additional case studies as our audit data becomes available. Each new case is reviewed by our clinical team and published with the patient’s consent.
PUBLISHED
Treatment-Resistant Depression
42-year-old London professional
10+ years of failed treatment
80% reduction in depression score
Photo is an anonymised representation to protect patient privacy.
PUBLISHED
Multi-Condition (Depression, Anxiety, OCD, PTSD)
Comprehensive recovery across 9 clinical scales
Every scale improved
Photo is an anonymised representation to protect patient privacy.
Coming Soon
Severe Suicidal Ideation
Anonymised case – Acute suicidal ideation resolved within 6 sessions
Ideation fully resolved
Photo is an anonymised representation to protect patient privacy.
Coming Soon
Complex PTSD
Anonymised case · 20+ years of treatment-resistant trauma symptoms
PTSD scores below clinical threshold
Photo is an anonymised representation to protect patient privacy.
Coming Soon
Treatment-Resistant OCD
Anonymised case · High-dose SSRI and ERP-resistant OCD
54% Y-BOCS reduction
Photo is an anonymised representation to protect patient privacy.
We publish new case studies as our clinical audit progresses. Want to be notified when new cases go live? Leave your email below.
- Honest Caveats
What individual cases don't tell you.
Case studies are powerful evidence, but they have limits. A single patient’s recovery is a single data point — not a guarantee, not a typical outcome, and not a substitute for a proper clinical assessment.
We publish these cases because they show what’s clinically possible, not because we’re promising every patient will see the same trajectory. Around 75%+ of our patients achieve a good response. The other 25–30% don’t, or don’t sustain it. We don’t pretend otherwise.
- Individual results vary. The cases here are real, but they're not averages.
- Around 5% of patients discontinue treatment before completing a full programme.
- 20–25% of patients don't respond within the first 10 sessions — though this drops to under 5% by session 20.
- Recovery isn't always linear. Most patients see ups and downs along the way.
- Maintenance matters. Around 20–30% of patients need occasional maintenance sessions to sustain gains long-term.
Your consultant will be honest with you about what realistic outcomes look like in your specific situation — at every stage of your programme.
- Video Testimonials
Hear directly from our patients.
Watch real patients share their experiences and how treatment transformed their lives.
- The Research
Beyond individual cases: peer-reviewed evidence.
Save Minds’ clinical outcomes are being prepared for publication in a peer-reviewed academic journal — the first audit of its kind from a UK private ketamine clinic. The dataset covers 140 patients across all five conditions we treat, with full clinical scoring at multiple time points.
We’re contributing to a growing body of international research showing that ketamine works for treatment-resistant conditions — and that careful, consultant-led delivery produces better outcomes than the unstructured approaches common in the US private market.
- 140 patients in the audit
- All 5 conditions represented
- Multi-point clinical scoring
- Submitted for peer review
We can’t share specific publication details until the journal embargo lifts. We’ll update this page when the paper publishes.
The numbers are real. So is the next step.
If you’ve read this far, you’ve seen the evidence. The first step is just a short eligibility check or a free, no-pressure call with our team.